Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| 1 |
Broadcom
AVGO
|
+$472M |
| 2 |
Advanced Micro Devices
AMD
|
+$296M |
| 3 |
Apple
AAPL
|
+$275M |
| 4 |
Qualcomm
QCOM
|
+$218M |
| 5 |
NVIDIA
NVDA
|
+$187M |
Top Sells
| 1 |
Amazon
AMZN
|
+$536M |
| 2 |
Uber
UBER
|
+$438M |
| 3 |
Chevron
CVX
|
+$280M |
| 4 |
Meta Platforms (Facebook)
META
|
+$264M |
| 5 |
CrowdStrike
CRWD
|
+$242M |
Sector Composition
| 1 | Technology | 19.65% |
| 2 | Healthcare | 18.08% |
| 3 | Consumer Discretionary | 13.75% |
| 4 | Industrials | 8.66% |
| 5 | Financials | 7.82% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
TPIC
3001
DELISTED
TPI Composites
TPIC
| $234K | ﹤0.01% |
58,686
+41,970
| +251% | +$167K |
|
3002
iShares Core MSCI Europe ETF
IEUR
$6.94B
| $233K | ﹤0.01% |
4,100
-1,500
| -27% | -$85.4K |
|
|
CBIO
3003
Crescent Biopharma, Inc. Common Stock
CBIO
$170M
| $233K | ﹤0.01% |
8,269
+6,852
| +484% | +$193K |
|
3004
MGE Energy Inc
MGEE
$3.05B
| $232K | ﹤0.01% |
3,100
-7,600
| -71% | -$568K |
|
3005
Jerash Holdings
JRSH
$44.1M
| $228K | ﹤0.01% |
74,835
-7,705
| -9% | -$23.5K |
|
3006
VistaGen Therapeutics
VTGN
$107M
| $226K | ﹤0.01% |
64,900
-44,900
| -41% | -$156K |
|
3007
OptimumBank Holdings
OPHC
$50.6M
| $225K | ﹤0.01% |
52,428
+9,228
| +21% | +$39.7K |
|
3008
CASI Pharmaceuticals
CASI
$36.6M
| $224K | ﹤0.01% |
40,800
+4,000
| +11% | +$22K |
|
3009
Skyward Specialty Insurance
SKWD
$1.93B
| $224K | ﹤0.01% |
+6,200
| New | +$224K |
|
3010
Citizens Community Bancorp
CZWI
$162M
| $223K | ﹤0.01% |
19,300
-6,100
| -24% | -$70.6K |
|
3011
Lyell Immunopharma
LYEL
$251M
| $221K | ﹤0.01% |
7,615
-13,560
| -64% | -$393K |
|
|
VLRS
3012
Controladora Vuela Compañía de Aviación
VLRS
$712M
| $221K | ﹤0.01% |
34,700
-41,000
| -54% | -$261K |
|
3013
Richmond Mutual Bancorp
RMBI
$140M
| $220K | ﹤0.01% |
18,742
| – | – |
|
3014
Transcontinental Realty Investors
TCI
$400M
| $219K | ﹤0.01% |
+7,900
| New | +$219K |
|
3015
Genpact
G
$7.49B
| $219K | ﹤0.01% |
6,800
-138,800
| -95% | -$4.47M |
|
3016
Sinclair Inc
SBGI
$933M
| $219K | ﹤0.01% |
16,400
-54,671
| -77% | -$729K |
|
3017
iShares Core High Dividend ETF
HDV
$11.7B
| $217K | ﹤0.01% |
2,000
-42,700
| -96% | -$4.64M |
|
3018
FB Financial Corp
FBK
$2.86B
| $217K | ﹤0.01% |
+5,562
| New | +$217K |
|
3019
DURECT Corp
DRRX
$59.3M
| $217K | ﹤0.01% |
168,266
+2,300
| +1% | +$2.97K |
|
|
BNR
3020
Burning Rock Biotech
BNR
$95.5M
| $217K | ﹤0.01% |
33,617
-653
| -2% | -$4.21K |
|
3021
Pulmatrix
PULM
$18.3M
| $217K | ﹤0.01% |
112,220
-2,600
| -2% | -$5.02K |
|
3022
AYTU BioPharma
AYTU
$20.5M
| $216K | ﹤0.01% |
74,123
+2,800
| +4% | +$8.18K |
|
3023
SB Financial Group
SBFG
$136M
| $213K | ﹤0.01% |
15,225
+100
| +0.7% | +$1.4K |
|
3024
ReNew
RNW
$2.78B
| $213K | ﹤0.01% |
34,100
+11,500
| +51% | +$71.8K |
|
3025
NeoGenomics
NEO
$966M
| $212K | ﹤0.01% |
15,300
-126,300
| -89% | -$1.75M |
|